Last reviewed · How we verify
ropinirole immediate release
Ropinirole is a dopamine agonist that works by activating dopamine receptors in the brain.
Ropinirole is a dopamine agonist that works by activating dopamine receptors in the brain. Used for Treatment of Parkinson's disease, Treatment of restless legs syndrome.
At a glance
| Generic name | ropinirole immediate release |
|---|---|
| Also known as | Ropinirole prolonged release |
| Sponsor | GlaxoSmithKline |
| Drug class | dopamine agonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This activation helps to increase the levels of dopamine in the brain, which can help to alleviate symptoms of Parkinson's disease. Ropinirole is a non-ergoline dopamine agonist, which means it does not have the same side effects as ergoline-based dopamine agonists.
Approved indications
- Treatment of Parkinson's disease
- Treatment of restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole (PHASE1, PHASE2)
- Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD (PHASE2)
- Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) (PHASE3)
- Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration) (PHASE2)
- Ropinirole Tablets In Young Patients With Restless Legs Syndrome (PHASE1)
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's (PHASE3)
- RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole (PHASE3)
- Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropinirole immediate release CI brief — competitive landscape report
- ropinirole immediate release updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI